The first 2 authors contributed equally to this work.
Patient-derived xenografts for individualized care in advanced sarcoma
Article first published online: 4 APR 2014
© 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 120, Issue 13, pages 2006–2015, 1 July 2014
How to Cite
Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., Harding, V., Vasquez, D., Krell, J., Ciznadija, D., Katz, A. and Sidransky, D. (2014), Patient-derived xenografts for individualized care in advanced sarcoma. Cancer, 120: 2006–2015. doi: 10.1002/cncr.28696
See related editorial on pages 1917–1919, this issue.
We are grateful to the patients who participated in this study.
- Issue published online: 17 JUN 2014
- Article first published online: 4 APR 2014
- Manuscript Accepted: 2 JAN 2014
- Manuscript Revised: 18 DEC 2013
- Manuscript Received: 26 SEP 2013
Vol. 120, Issue 22, 3588, Article first published online: 9 JUL 2014
Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard-of-care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in conducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient-derived xenografts using a proprietary method (“TumorGrafts”).
Tumors resected from 29 patients with sarcoma were implanted into immunodeficient mice to identify drug targets and drugs for clinical use. The results of drug sensitivity testing in the TumorGrafts were used to personalize cancer treatment.
Of 29 implanted tumors, 22 (76%) successfully engrafted, permitting the identification of treatment regimens for these patients. Although 6 patients died before the completion of TumorGraft testing, a correlation between TumorGraft results and clinical outcome was observed in 13 of 16 (81%) of the remaining individuals. No patients progressed during the TumorGraft-predicted therapy.
The current data support the use of the personalized TumorGraft model as an investigational platform for therapeutic decision-making that can guide treatment for rare tumors such as sarcomas. A randomized phase 3 trial versus physician's choice is warranted. Cancer 2014;120:2006–2015. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.